Clinical Phenotyping for Prognosis and Immunotherapy Guidance in Bacterial Sepsis and COVID-19

Crit Care Explor. 2024 Sep 10;6(9):e1153. doi: 10.1097/CCE.0000000000001153. eCollection 2024 Sep 1.

Abstract

Objectives: It is suggested that sepsis may be classified into four clinical phenotypes, using an algorithm employing 29 admission parameters. We applied a simplified phenotyping algorithm among patients with bacterial sepsis and severe COVID-19 and assessed characteristics and outcomes of the derived phenotypes.

Design: Retrospective analysis of data from prospective clinical studies.

Setting: Greek ICUs and Internal Medicine departments.

Patients and interventions: We analyzed 1498 patients, 620 with bacterial sepsis and 878 with severe COVID-19. We implemented a six-parameter algorithm (creatinine, lactate, aspartate transaminase, bilirubin, C-reactive protein, and international normalized ratio) to classify patients with bacterial sepsis intro previously defined phenotypes. Patients with severe COVID-19, included in two open-label immunotherapy trials were subsequently classified. Heterogeneity of treatment effect of anakinra was assessed. The primary outcome was 28-day mortality.

Measurements and main results: The algorithm validated the presence of the four phenotypes across the cohort of bacterial sepsis and the individual studies included in this cohort. Phenotype α represented younger patients with low risk of death, β was associated with high comorbidity burden, and δ with the highest mortality. Phenotype assignment was independently associated with outcome, even after adjustment for Charlson Comorbidity Index. Phenotype distribution and outcomes in severe COVID-19 followed a similar pattern.

Conclusions: A simplified algorithm successfully identified previously derived phenotypes of bacterial sepsis, which were predictive of outcome. This classification may apply to patients with severe COVID-19 with prognostic implications.

MeSH terms

  • Aged
  • Algorithms*
  • Bacterial Infections / diagnosis
  • COVID-19* / immunology
  • COVID-19* / mortality
  • COVID-19* / therapy
  • Female
  • Greece / epidemiology
  • Humans
  • Immunotherapy* / methods
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use
  • Male
  • Middle Aged
  • Phenotype*
  • Prognosis
  • Retrospective Studies
  • SARS-CoV-2
  • Sepsis* / diagnosis
  • Sepsis* / immunology
  • Sepsis* / mortality
  • Sepsis* / therapy

Substances

  • Interleukin 1 Receptor Antagonist Protein